Legend Biotech FY2025 EPS Estimate Lifted by HC Wainwright

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Research analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of Legend Biotech in a report released on Thursday, January 22nd. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($1.32) for the year, up from their prior forecast of ($1.34). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech’s Q4 2025 earnings at $0.12 EPS.

Legend Biotech (NASDAQ:LEGN) last posted its earnings results on Wednesday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $272.33 million for the quarter, compared to the consensus estimate of $277.91 million. Legend Biotech had a negative return on equity of 24.47% and a negative net margin of 26.37%.Legend Biotech’s revenue was up 70.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.34) earnings per share.

Other analysts have also issued reports about the stock. UBS Group cut their target price on shares of Legend Biotech from $54.00 to $48.00 and set a “buy” rating for the company in a research report on Monday, December 8th. Barclays dropped their price target on shares of Legend Biotech from $94.00 to $90.00 and set an “overweight” rating on the stock in a research note on Thursday, November 13th. Johnson Rice set a $60.00 price objective on Legend Biotech in a research note on Friday, October 17th. Oppenheimer began coverage on Legend Biotech in a research report on Wednesday, January 7th. They set an “outperform” rating and a $75.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Legend Biotech in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $58.50.

Legend Biotech Price Performance

NASDAQ LEGN opened at $19.01 on Monday. The company has a 50-day moving average price of $23.93 and a 200-day moving average price of $31.22. Legend Biotech has a 52 week low of $18.99 and a 52 week high of $45.30. The company has a quick ratio of 2.80, a current ratio of 2.86 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $3.51 billion, a P/E ratio of -29.25 and a beta of 0.12.

Institutional Investors Weigh In On Legend Biotech

Institutional investors have recently bought and sold shares of the business. Clear Creek Financial Management LLC bought a new stake in Legend Biotech during the fourth quarter valued at about $217,000. Harbor Capital Advisors Inc. grew its position in shares of Legend Biotech by 24.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 30,141 shares of the company’s stock worth $655,000 after purchasing an additional 5,996 shares in the last quarter. Aberdeen Group plc raised its stake in Legend Biotech by 62.5% during the 4th quarter. Aberdeen Group plc now owns 29,782 shares of the company’s stock valued at $647,000 after purchasing an additional 11,456 shares during the period. Tempus Wealth Planning LLC lifted its holdings in Legend Biotech by 51.3% in the 4th quarter. Tempus Wealth Planning LLC now owns 12,217 shares of the company’s stock worth $266,000 after purchasing an additional 4,141 shares in the last quarter. Finally, Banque Pictet & Cie SA bought a new position in Legend Biotech in the 4th quarter worth approximately $315,000. Hedge funds and other institutional investors own 70.89% of the company’s stock.

Legend Biotech Company Profile

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.